Less than 1 in 6 healthcare workers get COVID-19 booster shot: CDC
But a recent survey of healthcare workers found that while many personnel believe that COVID-19 is a serious health threat, ...
Study reveals stubborn mistrust in COVID-19 vaccine science
A study conducted by researchers from the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the ...
NBC Los Angeles2d
Do the Covid vaccines provide long-lasting protection?
The Centers for Disease Control and Prevention now recommends that people ages 65 and up and those with weakened immune ...
HealthDay on MSN4d
American College of Allergy, Asthma & Immunology, Oct. 24-28
The annual meeting of the American College of Allergy, Asthma & Immunology was held from Oct. 24 to 28 in Boston, drawing ...
Why Are So Many Right-Wing Podcasts at the Top of the Charts? It’s Grim.
There’s a reason conservative-leaning figures like Tucker Carlson, Candace Owens, and Charlie Kirk have taken over the ...
Is the updated COVID vaccine a good match for the current variant and the emerging strain?
Northeastern University professors of pharmacy say the updated COVID-19 vaccines available for fall and winter of 2024 are a ...
Evaxion Biotech: Evaxion announces business update and third quarter 2024 financial results
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business up ...
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
Preliminary Q3 2024 PEMGARDA (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with approximately $107 million in cash and cash equivalentsExpects to finish 2024 with $65 million ...
A vote for Donald Trump is a vote for school shootings and measles
That’s a vote for Donald Trump — a vote for the line on the school shootings chart to keep going up, forever It’s the same with vaccines, which are a near-perfect collective action problem — they are ...
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ...
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...